Business Description
IDEXX Laboratories Inc
NAICS : 325412
SIC : 2835
ISIN : US45168D1046
Share Class Description:
FRA:IX1: Ordinary SharesDescription
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.31 | |||||
| Equity-to-Asset | 0.48 | |||||
| Debt-to-Equity | 0.62 | |||||
| Debt-to-EBITDA | 0.8 | |||||
| Interest Coverage | 33.72 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 16.31 | |||||
| Beneish M-Score | -2.39 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.8 | |||||
| 3-Year EBITDA Growth Rate | 16.7 | |||||
| 3-Year EPS without NRI Growth Rate | 14.8 | |||||
| 3-Year FCF Growth Rate | 13.9 | |||||
| 3-Year Book Growth Rate | 34.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 10.41 | |||||
| Future 3-5Y Total Revenue Growth Rate | 7.22 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.09 | |||||
| 9-Day RSI | 42.31 | |||||
| 14-Day RSI | 43.98 | |||||
| 6-1 Month Momentum % | -12.48 | |||||
| 12-1 Month Momentum % | -20.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.42 | |||||
| Quick Ratio | 1.03 | |||||
| Cash Ratio | 0.31 | |||||
| Days Inventory | 93.5 | |||||
| Days Sales Outstanding | 46.75 | |||||
| Days Payable | 27.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 1 | |||||
| Shareholder Yield % | 2.39 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 60.72 | |||||
| Operating Margin % | 28.92 | |||||
| Net Margin % | 22.53 | |||||
| FCF Margin % | 20.62 | |||||
| ROE % | 57.37 | |||||
| ROA % | 26.3 | |||||
| ROIC % | 35.51 | |||||
| ROC (Joel Greenblatt) % | 92 | |||||
| ROCE % | 49.13 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 40.01 | |||||
| Forward PE Ratio | 35.29 | |||||
| PE Ratio without NRI | 37.86 | |||||
| Shiller PE Ratio | 62.23 | |||||
| Price-to-Owner-Earnings | 46.94 | |||||
| PEG Ratio | 2.12 | |||||
| PS Ratio | 9.02 | |||||
| PB Ratio | 21.04 | |||||
| Price-to-Tangible-Book | 30.97 | |||||
| Price-to-Free-Cash-Flow | 43.75 | |||||
| Price-to-Operating-Cash-Flow | 37.83 | |||||
| EV-to-EBIT | 30.78 | |||||
| EV-to-Forward-EBIT | 28.82 | |||||
| EV-to-EBITDA | 27.69 | |||||
| EV-to-Forward-EBITDA | 25.6 | |||||
| EV-to-Revenue | 9.02 | |||||
| EV-to-Forward-Revenue | 8.25 | |||||
| EV-to-FCF | 43.74 | |||||
| Price-to-Projected-FCF | 3.69 | |||||
| Price-to-DCF (Earnings Based) | 1.21 | |||||
| Price-to-DCF (FCF Based) | 1.51 | |||||
| Price-to-Median-PS-Value | 0.92 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.31 | |||||
| Price-to-Graham-Number | 7.22 | |||||
| Earnings Yield (Greenblatt) % | 3.25 | |||||
| FCF Yield % | 2.33 | |||||
| Forward Rate of Return (Yacktman) % | 18.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
IDEXX Laboratories Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3,525.023 | ||
| EPS (TTM) (€) | 9.502 | ||
| Beta | 1.57 | ||
| Volatility % | 26.47 | ||
| 14-Day RSI | 43.98 | ||
| 14-Day ATR (€) | 4.251867 | ||
| 20-Day SMA (€) | 405.345 | ||
| 12-1 Month Momentum % | -20.84 | ||
| 52-Week Range (€) | 372.9 - 536.8 | ||
| Shares Outstanding (Mil) | 81.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
IDEXX Laboratories Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
IDEXX Laboratories Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
IDEXX Laboratories Inc Frequently Asked Questions
What is IDEXX Laboratories Inc(FRA:IX1)'s stock price today?
The current price of FRA:IX1 is €397.70. The 52 week high of FRA:IX1 is €536.80 and 52 week low is €372.90.
When is next earnings date of IDEXX Laboratories Inc(FRA:IX1)?
The next earnings date of IDEXX Laboratories Inc(FRA:IX1) is 2025-02-05 Est..
Does IDEXX Laboratories Inc(FRA:IX1) pay dividends? If so, how much?
IDEXX Laboratories Inc(FRA:IX1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers